Download PDF
Semin Thromb Hemost 2006; 32(1): 077-078
DOI: 10.1055/s-2006-933343
ERRATA

Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The P2 Receptors and Congenital Platelet Function Defects

Marco Cattaneo
Further Information

Publication History

Publication Date:
15 February 2006 (online)

    Permissions and Reprints

Correction to:

The P2 Receptors and Congenital Platelet Function DefectsSemin Thromb Hemost 2005; 31(02): 168-173
DOI: 10.1055/s-2005-869522

In the above-mentioned article, published in Seminars in Thrombosis and Hemostasis 2005; Volume 31, Number 2, pages 168-173, page 170, paragraph 1, line 3 should read:

P2Y12 is the target of efficacious antithrombotic agents like ticlopidine and clopidogrel,2,32 which are already used in clinical practice, and the AR-C compounds,33 one of which is currently under evaluation in clinical trials.

 Professor
Marco Cattaneo

Unit of Hematology and Thrombosis, Ospedale San Paolo, DMCO University of Milan

Via di Rudinì, 8, 20142 Milan, Italy

Email: marco.cattaneo@unimi.it

      >